Longevity Health HoldingsXAGE -23.30%6 EBITDA Margin % is -354.85% as of Mar. 2026. GuruFocus rates XAGE with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 1,951 Consumer Packaged Goods companies, Longevity Health Holdings ranks worse than 98.36% on this metric.
Longevity Health Holdings (OTCPK:XAGE) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Longevity Health Holdings EBITDA Margin % Related Terms
Longevity Health Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XAGE vs SNBH, SKVI, PG: EBITDA Margin % Comparison
For the Household & Personal Products subindustry, Longevity Health Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Longevity Health Holdings EBITDA Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Longevity Health Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Longevity Health Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Longevity Health Holdings (XAGE) has a EBITDA Margin % of -354.85% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Longevity Health Holdings and its competitors. According to the industry distribution chart, Longevity Health Holdings ranks #1919 out of 1951 companies in the Consumer Packaged Goods industry, placing it in the top 98.4%.
Is Longevity Health Holdings' EBITDA Margin % too high?
Longevity Health Holdings' current EBITDA Margin % is -354.85%. Based on the distribution chart, Longevity Health Holdings ranks #1919 out of 1951 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Longevity Health Holdings has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Longevity Health Holdings' EBITDA Margin % compare to SNBH and SKVI?
According to the Consumer Packaged Goods industry distribution chart, Longevity Health Holdings ranks #1919 out of 1951 companies for EBITDA Margin %. This places Longevity Health Holdings in the lower half of its industry. The industry median EBITDA Margin % is 8.97. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Consumer Packaged Goods company?
The median EBITDA Margin % among Consumer Packaged Goods companies is 8.97, based on 1,951 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Longevity Health Holdings and its competitors. For the Consumer Packaged Goods industry, the median EBITDA Margin % is 8.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Longevity Health Holdings's current EBITDA Margin % is -354.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Health Holdings stock overvalued right now?
Longevity Health Holdings (XAGE) has a current EBITDA Margin % of -354.85%. The current EBITDA Margin % is -354.85%. Longevity Health Holdings' overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Longevity Health Holdings (XAGE), the current EBITDA Margin % is -354.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Longevity Health Holdings Inc is a bio-aesthetics company focused on longevity and healthy aging. The company develops cosmetic skincare and haircare products designed to support skin and hair health, tailored to meet the technical requirements of professional care providers as well as retail consumers. Its product pipeline also includes regenerative bone and tissue healing solutions, although further research and development in this area has been paused. The company markets its cosmetic products in the United States through business-to-business, direct-to-consumer, and distributor sales channels.
6GF Score
Get the complete analysis for XAGE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XAGE has been successfully added to your 
